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Major depressive disorder (MDD) is a multifactorial disorder known to be influenced
by both genetic and environmental factors. MDD presents a heritability of 37%, and
a genetic contribution has also been observed in studies of family members of
individuals with MDD that imply that the probability of suffering the disorder is
approximately three times higher if a first-degree family member is affected.
Childhood maltreatment and stressful life events (SLEs) have been established as
critical environmental factors that profoundly influence the onset of MDD. The
serotonin pathway has been a strong candidate for genetic studies, but it only
explains a small proportion of the heritability of the disorder, which implies the
involvement of other pathways. The serotonin (5-HT) pathway interacts with the
stress response pathway in a manner mediated by the hypothalamic-pituitary-
adrenal (HPA) axis. To analyze the interaction between the pathways, we propose
the use of a synchronous Boolean network (SBN) approximation. The principal aim of
this work was to model the interaction between these pathways, taking into
consideration the presence of selective serotonin reuptake inhibitors (SSRIs), in order
to observe how the pathways interact and to examine if the system is stable.
Additionally, we wanted to study which genes or metabolites have the greatest
impact on model stability when knocked out in silico. We observed that the
biological model generated predicts steady states (attractors) for each of the
different runs performed, thereby proving that the system is stable. These attractors
changed in shape, especially when anti-depressive drugs were also included in the
simulation. This work also predicted that the genes with the greatest impact on
model stability were those involved in the neurotrophin pathway, such as CREB,
BDNF (which has been associated with major depressive disorder in a variety of
studies) and TRkB, followed by genes and metabolites related to 5-HT synthesis.
Keywords: Serotonin, HPA, Major depressive disorder, Stress, Synchronous boolean
networks, BDNF, TRkB© 2013 Moreno-Ramos et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
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Major depressive disorder (MDD) is one of the most common debilitating mood disorders
worldwide and is becoming increasingly prevalent in children and adolescents. Approxi-
mately 15% of the population is estimated to be affected with this disorder at least once in
their lifetime [1-4]. MDD has been projected to become the second leading cause of dis-
ability worldwide by 2020 according to the World Health Organization (WHO).
MDD is a multifactorial disorder known to be influenced by both genetic and environ-
mental factors. The heritability of MDD is estimated to be 0.37 (95% confidence interval
(CI) 0.31-042) based on data from twin studies, and a genetic contribution has also been
observed in family studies of individuals with MDD that imply that the probability of suf-
fering the disorder is approximately three times higher if a first-degree family member is
affected [5,6].
Childhood maltreatment and stressful life events (SLEs) have been established as critical
environmental factors that profoundly influence the onset of MDD [7,8]; however, the
question of why some individuals develop MDD when exposed to stressful events and
some do not has been difficult to answer. An initial attempt to answer this question was
made in 2003 by Caspi et al., who elegantly demonstrated that the risk of developing
MDD is higher when an individual has experienced various stressor events during child-
hood. In this work, they evaluated the possible association of a genetic variant of the sero-
tonin transporter (5-HTT) with maltreatment [9]. This gene x environment interaction
approach in which 5-HTT gene variations are proposed to influence the likelihood of
stressful life events resulting in MDD has not been fully supported by recent studies,
suggesting that other pathways, such as those involved in stress responses, might also be
involved in the development of MDD [10,11]. Moreover, one of the most common types
of antidepressant used is the Selective Reuptake Inhibitors (SSRIs). SSRIs are designed to
block the 5-HTT. Therefore, 5-HT homeostasis in the brain is related to the disease,
which makes the 5-HT pathway a strong candidate for studies of MDD [12].
More recently, it has been demonstrated that neurotrophin signaling directly interacts
with the serotonin pathway, therefore making it another good candidate for MDD studies.
Brain-derived neurotrophic factor (BDNF) is a growth factor involved in regulating the
survival and maturation of serotonin (5-HT) neurons during development and in regulat-
ing synaptic plasticity throughout life. In the dorsal raphe nuclei (DRN) cell, BDNF acti-
vates genes in the serotonin pathway, such as those encoding the serotonin transporter
(5-HTT) and the enzymes required for 5-HT synthesis. The 5-HT released from the raphe
nucleus cells activate serotonin post-synaptic receptors and autoreceptors such as 5-HT1A.
Autoreceptor stimulation by 5-HT leads to a blockade of BDNF regulatory genes and,
therefore, a decrease in BDNF synthesis [13-15].
The stress response activates a series of processes in the hypothalamus-pituitary-adrenal
(HPA) axis culminating in the release of cortisol by the adrenal glands [16]. The gluco-
corticoid receptor is expressed in serotoninergic neurons [17-19], which is indicative of
glucocorticoid-exerted control in these neurons. On the other hand, both stress and glu-
cocorticoids are known to decrease brain levels of BDNF in rodents and post-mortem hu-
man tissue [20]. Taken together, this information suggests the existence of a cycle
involving these three pathways (the 5-HT regulation pathway, the stress response pathway
and the BDNF regulation pathway), which are essential to enable the serotonin system to
respond to various stimuli throughout life.
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sponse) interactions between the 5-HT regulation pathway and the neurotrophin signal-
ing pathway. Synchronous Boolean networks (SBNs) have proven to be a valuable model
for understanding how a large number of components (nodes) in a network interact with
each other. The logic of SBNs is based on the use of binary values, 0 as “inactive” and 1 as
“active”, to model a complex system [21,22]. SBNs are networks that update their nodes
synchronously in a discrete time step [23]. Since we are analyzing a large complex net-
work (41 nodes), we chose synchronous update since this type of modeling changes ex-
pression, activation or inactivation of different nodes simultaneously in a discrete time
[24], feature observed in various biological systems [25,26]. Moreover, as we are dealing
with a large network, this updating approximation is computationally feasible.
Through this type of network modeling, it is possible to understand and annotate com-
plex pathways. SBN approximations have been used to model the orientation pathways by
which neural crest stem cells give rise to two different types of sensorial cells [27], and it
has also been used to model biofilm formation in the E. coli strain K-12 [28]. Furthermore,
this approach has also been applied to search for new candidate genes in schizophrenia
[21] and as a modeling technique in cancer studies [29].
The aim of this work was to use a Boolean approximation to analyze an integrated net-
work involving the 5-HT neurotransmitter pathway, neurotrophin signaling and the HPA
cortisol synthesis pathway in the presence and absence of stress and serotonin selective re-
uptake inhibitors (SSRIs). We also evaluated network stability and the effects that knocked-
out genes had on the network to search for probable candidate genes involved in MDD.Methods
The Methods section is depicted in Figure 1 to clarify the methodology used.Model definition and network simulation
The biological information used to generate the network is shown in Appendix A and
was analyzed using an SBN approximation. The model was simulated using the Random
Boolean Networks (RBN) toolbox (free download at http://www.teuscher.ch/rbntoolbox)
for Matlab® by using the tools that allow for well-defined connections among nodes. Bool-
ean logic was applied to identify the logic operators (“AND” and “AND-NOT”) that allow
the model to simulate the network [30]. The Boolean simplification gave 41 nodes that
were logically connected and allowed the construction of a rules-matrix, which defines
the logic transition rules for each node in the network, and a connection-matrix, which
explains the connectivity of the nodes. Both matrixes are in conjunction the mathematical
model behind the simulations performed.
The rules-matrix size was 2kxN (N nodes and k connections). Each node has k possible
entrances that only generate two responses (1 or 0 for on or off, respectively). Our net-
work has 41 nodes and up to 4 entrances with a rules-matrix size of 24x41. Each column
of this matrix is created using 41 different matrices, where each of these matrices holds
the response of each node according to the 4 different binary organized entrances. The
connection-matrix created has a size of NxN where each of the matrix entrances (i,j) de-
fines the number of connections from node i to node j with a column sum restriction
equal to k.
Figure 1 A flow chart illustrating the methodology used to model the network. For more
information, refer to the Methods section.
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for the nodes corresponding to stress and to SSRI, which were permuted between 1 and 0
(on or off). Therefore, four initial states were generated: 1) Basal Model: all 41 nodes ini-
tially active except the stress and SSRI nodes, 2) Antidepressant Model: all 41 nodes active
except the stress node, 3) Chronic Stress Model: all 41 nodes active except the SSRI node
and 4) Complete Model: all 41 nodes active. In our model, the stress, tryptophan (TRP)
and selective serotonin reuptake inhibitor (SSRI) nodes remain in a steady state through-
out the simulations because they are not downregulated by any other node. To verify that
the network was stable, attractors were obtained from each simulation. The simulations
performed are shown in Figure 1. Each of the four simulations were performed in a
2.8GHz Intel Core 2 Duo with 4GB RAM, taking ~5 s per run.Stability analysis through in silico knockouts
In silico knockouts were generated for all nodes and their effects on network stability
(Convergence/divergence from the same initial condition in a discrete time [21]) were
evaluated by comparing two networks (mutated and non-mutated) simulated in parallel.
In the two networks, the state of SSRI was fixed to 0 (i.e., switched off) because it is not a
normal biological component of the pathway. Therefore, the possible states for the two
networks were reduced from 241 to 241-1. The simulations performed were run with the
same discrete time span (t = 100) to allow calculation of the normalized Hamming dis-
tance (number of positions, in a vector or matrix, at which the corresponding component
is different divided by the number of total components) between each of the states at the
same discrete time throughout the whole time span (100 hamming distances calculated).
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we consider normalized Hamming distance as an adequate measure to observe the con-
vergence/divergence, at the same discrete time, between the two models (mutated and
non-mutated) [21].
The initial states were randomly selected but they were the same for both networks,
which allowed a statistical measurement of convergence/divergence of the network dy-
namics [21]. Both networks were run 1000 times, and the mean normalized Hamming
distance and its standard deviation were calculated and plotted against the discrete time
to determine the perturbation when the genes in question were knocked-out. Even though
we know that there are other metrics to infer difference/similarity between two objects,
we consider normalized Hamming distance as an adequate measure to observe the con-
vergence/divergence, at the same discrete time, between the two models (mutated and
non-mutated) [21]. The biological reason behind this approximation is that most genetic
diseases are a product of a cascade block that leads to an undesired stable state.
To evaluate the accuracy of the mean normalized Hamming distances, a bootstrapping
method was used to calculate the mean deviation error and thereby validate the statistical
significance as the data did not fit a defined probability distribution [31,32]. All the simu-
lations were performed in a single code line in a 2.8GHz Intel Core 2 Duo with 4GB
RAM, taking ~7.4 h.Results and discussion
Model definition: genetic pathway and Boolean logic applied to the model
The network was constructed using the DRN cell and hippocampal serotonin-sensitive
cell brain areas in combination with the stress response pathway involving the periven-
tricular nucleus, the pituitary gland and the cortisol-secreting adrenal gland (Figure 2).
The network was simplified using a Boolean approximation as depicted in Figure 3.Network simulation
The four simulations (Figure 1) demonstrated network stability by means of an attractor
(cycling pattern). Figure 4 depicts the results of the four simulations described in Figure 1
and Methods section. It indicates that all four models show attractor stability. Each of the
individual models was described separately below (Section 2, subsection 2.2.). The nodes
involved in G-protein signaling (in both presynaptic and postsynaptic neuron) are not
shown since they are ubiquitously expressed. Thus, no effect is observed when deleting
these nodes. This reduces the nodes shown in Figure 4 from 41 to 32. Hence, G-protein
signaling will not be a cause of MDD.
In the Basal Model (Figures 1 and 4A), we found that the approximation is reliable be-
cause the autoreceptor (5-HT1A
* ) turns 5-HT synthesis and transportation pathways off,
and this finding agrees with those of previous in vivo studies [33-35] (see Appendix A for
pathway details).
The Antidepressant Model (Figure 1) demonstrates active synthesis, transport, degrad-
ation and activation of the hippocampal serotonin-sensitive neuron (Figure 4B). A limita-
tion to Boolean modeling is that it is concentration independent and therefore it cannot
take into account the complex kinetics involved in controlling the serotonin system
in vivo. It is believed that SSRIs block the serotonin transporter and thereby increase 5-
Figure 2 The genetic pathway predicted to regulate the interaction between 5-HT synthesis, transport and degradation and the stress response mediated by the HPA axis. This figure





















Figure 3 A simplified model of the regulatory interactions between the serotonin and stress
response pathways mediated by the HPA axis. AND/NOT operators are included to show the Boolean
logic used. When no operator is shown between the nodes, the activation state is given by any of the
nodes upstream. * Nodes located in the dorsal Raphe nucleus (DRN) cells.
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the 5-HT1A
* autoreceptor [33-36]. This interaction between synaptic 5-HT and the
5-HT1A
* autoreceptor is impossible to observe in a Boolean simulation because, as stated
above, no data on concentrations or kinetics can be used.
Interestingly, in this simulation we did observe a constant synthesis of 5-HT when ad-
ministering SSRIs (Figure 4B). This result suggests that other pathways might be
interacting with 5-HT, as has also been implied by the results of other studies [37,38].
However, care should be taken when considering this possibility because the model can-
not consider the effects of 5-HT concentration on its homeostasis.
The Chronic Stress Model (Figure 1) considers a stressor event in the absence of SSRIs
(Figure 4C). It is well known that stress events activate the HPA axis (Figure 2). The nodes
related to the stress response mediated by the HPA axis (VPA, CRH, HACT, GR/MR(pg)
and GR/MR(pvn)), indicate a strong regulation that is evident in the constant cycling pat-
tern that exists while the stress node is in the ‘on’ state. Furthermore, this stress response
model shows that the cortisol receptor in serotonin DRN cells blocks TPH and deregu-
lates the serotonin cyclic synthesis and transport pathways. This strong negative effect
was observed in the model 57 discrete times as a longer attractor and has been reported
to affect serotonin by blocking its synthesis through the activity of increased levels of cor-
tisol [39]. Finally, the Complete Model (Figure 1) considered both the SSRI effect and the
stress response (Figure 4D). We observed that the effect of SSRIs does not produce the
same long cyclic pattern that was generated when stress alone was present (Figure 4C).
Figure 4 Results obtained for all the runs performed with the model generated by a Boolean
approximation using Synchronous Boolean Networks (SBNs). Nodes related to G-protein signaling are
not shown. An input vector of ones was used for all nodes except the SSRI and stress nodes, which were
activated or deactivated to generate 4 possible simulations. A. The pattern obtained when stress and
SSRI were both in the ‘off’ state (basal system) and the other nodes were ‘on’. B. The effect of SSRI
activity on the serotonin regulation pathway under unstressed conditions is shown. Notice that the
antidepressant activity blocks 5-HTT and 5-HT1A
* , causing 5-HT synthesis, degradation and transport
pathways to remain active. C. The pattern generated when the stress node is ‘on’ and SSRI is ‘off’. In this
case, a cyclical pattern was observed for nodes related to 5-HT synthesis, transportation and degradation.
This figure also shows that while the stress response is well regulated, a persistent stressed state activates
the HPA axis over time. D. SSRI clearly regulates the cyclical pattern shown in C, but it does not cause
the same pattern shown in B. This is in line with expectation and demonstrates that SSRIs do not have
any effect when the patient is stressed.
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similarities to the Basal Model simulation (Figure 4A). The pattern shows that SSRIs regu-
late the serotonin pathway when chronic stress is present, but it does not allow for the
constant presence of 5-HT in the synaptic cleft. Accordingly, here we show that SSRIs act
differently depending on the presence or absence of chronic stress, indicating that stress
deregulates the effect of the SSRIs.
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and connectivity, it is well known that treatment with SSRI-type antidepressants seems to
modulate hippocampal neurogenesis, which is essential in MDD treatment [40,41].
Hence, this work leaves the door open to future simulations to consider not only the 5-
HT regulation and BDNF regulation pathways but also the BDNF mechanisms that
modulate neural plasticity in serotoninergic neurons.Stability analysis through knockouts in silico
In our network stability analysis, 27 nodes where initially considered (Table 1). However,
because 4 of these nodes corresponded to glucocorticoid receptors, they were treated as a
single node in our analysis. Therefore, 23 nodes were evaluated independently for their ef-
fects on network stability. Knock-out networks were simulated in parallel with wild type
networks. When the Hamming distance and its mean were plotted versus discrete time,
the results indicated that the nodes corresponding to TrkB, BDNF and CREB have theTable 1 Genes selected for knockout analysis
Node Name Gene or Metabolite
TRP Tryptophan
TPH 2 Tryptophan hydroxylase 2
5-HTP 5-hydroxytryptophan
AADC Aromatic L-amino decarboxylase
5-HT* Serotonin in the DRN
MAOA Monoamine-oxidase A
SL18A2 Solute carrier 18A-2
5-HT Synaptic serotonin
5-HT1A Postsynaptic 5-HT receptor 1Aa
K-Channel Presynaptic potassium channel a
K+ Postsynaptic potassium
5-HT1A* Presynaptic 5-HT receptor 1Aa
K-Channel* Presynaptic potassium channel a
K + * Presynaptic potassium
5-HTT Serotonin transporter
CREB cAMP-response element binding
BDNF Brain-derived neurotrophic factor
TRkB Tyrosine kinase B




GR/MR(PG) Glucocorticoid/Mineralocorticoid receptor (pituitary gland)
b
GR/MR(PVN) Glucocorticoid/Mineralocorticoid receptor (paraventricular nucleus)
b
GR/MR(DRN) Glucocorticoid/Mineralocorticoid receptor (dorsal raphe nucleus)
b
GR/MR(SSC) Glucocorticoid/Mineralocorticoid receptor (sensitive serotonin cell)
b
NFkB Nuclear factor
a. Gene knocked out in a specific tissue, b. gene knocked out globally, * presynaptic node expressed in the dorsal raphe
nucleus. (DRN) dorsal raphe nucleus, (PG) pituitary gland, (PVN) paraventricular nucleus, (SSC) sensitive serotonin cell.
Moreno-Ramos et al. Theoretical Biology and Medical Modelling 2013, 10:59 Page 10 of 15
http://www.tbiomed.com/content/10/1/59greatest effects on network stability (Figure 5). Although the data indicate that the BDNF
and 5-HT synthesis pathways have an impact on network stability, it is important to con-
sider that they are the mean Hamming distances reported when those nodes were
knocked-out. Consequently, we decided to evaluate the accuracy of the results by calculat-
ing the deviation error using the bootstrapping method. Figure 6 confirms that nodes re-
lated to the BDNF pathway and those related to 5-HT synthesis generate a disorder in the
network when they are knocked out, thereby reinforcing the theory that genes related to
the BDNF pathway (CREB, BDNF and possibly TRkB) are high-impact risk factors in-
volved in the development of MDD.
Various authors have reported low BDNF serum concentrations in depressive patients
and in association with suicidal behavior [42-44]. BDNF administration to the DRN cells
has been observed to have an antidepressant effect [45]. Additionally, the Val66M Met
polymorphism in BDNF has been associated with depressive states [46]. Figures 5 and 6
also show that if any of the nodes related to either the 5-HT synthesis pathway or transport
to the synaptic cleft is mutated, there is an effect on system stability. This may explain why
patients with MDD synthesize lower levels of serotonin than healthy controls [47].
In our model, we considered the neural connections that are already formed in an adult.
Thus, the BDNF biological functions examined are not related to neural plasticity but in-
stead relate to the DRN serotoninergic phenotype. In the model, stress does not down-
regulate BDNF expression in DRN cells (Figures 4A and 3C). However, an interaction
between stress and the expression and biological functions of BDNF, mostly at early
developmental stages, has been described [48]. In fact, it has been found that the cross-
sectional area of the DRN is decreased in MDD patients, possibly due to a neuropil reduc-
tion [49]. Neuropil reduction is related to low BDNF and TRkB concentrations [50], and
stress may therefore affect BDNF regulation pathways in the DRN cells. Further studies
are needed to confirm this possibility.
A very important finding is the identification of the TRkB receptor as another poten-
tial risk factor for MDD. TRkB mRNA has been found to be expressed in the DRN, as
has its ligand, BDNF, and both are essential to the serotoninergic phenotype of the cellsFigure 5 The effects of knocking out key nodes in the model. The importance of individual nodes was
determined based on the mean Hamming distance calculated from 100 discrete runs following node
knockout in the model. The nodes corresponding to CREB, BDNF and TRkB had the greatest negative effect
on network stability when knocked out, while those related to 5-HT synthesis had the next greatest
negative effect.
Figure 6 Results obtained by the application of the bootstrapping method to calculate the
deviation error (only shown for the 100th time step because the system has reached stability).
These results show strong similarity to those obtained by calculation of the mean Hamming distance
(Figure 5).
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or with attempted suicide in German and African American populations [52]. Moreover,
glucocorticoids reduce TRkB protein concentration in the prefrontal cortex and the
hippocampus in the mouse brain, which results in the development of depressive-like be-
havior and anxiety [53]. Therefore, we consider this a plausible candidate for future MDD
association studies in different populations or other simulation studies where other tissues
and pathways are taken into account.Conclusions
We constructed a stable model of depression. In this model, stress modifies the serotonin
regulation pathway as predicted. The effect of antidepressants observed in the model agrees
with expectations because the model incorporating SSRI activity exhibited increased DBNF
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normalize the regulation pattern when the patient has an acute stress event.
The patterns shown have been derived from biological data and are an excellent tool
for visualizing the complex system that they model. However, the system is unable to
accurately model the pathway in its entirety due to the lack of sufficient biological in-
formation. Thus, we propose that the BDNF regulatory pathway, especially TRkB, must
be studied in more detail to clarify some aspects of MDD etiology.Appendix A
The genetic regulation network obtained was initially based on the interaction pathway
found in www.pantherdb.org with the accession number P04375 [54]. We performed a
thorough bibliographic mining following the procedure described in [55]. The network
generated is described briefly below.
The serotonin neurotransmitter (5-HT) is synthesized in the DRN cells by tryptophan
(TRP) hydrolysis mediated by the enzyme tryptophan hydroxylase (TPH). This reaction pro-
duces 5-hydroxytryptophan (5-HTP), thus becoming the main source of 5-HT. Serotonin
can be degraded by monoamine oxidase A (MAOA) to produce 5-hydroxyindoleacetic
acid (5-HIAA) [56-60]. Serotonin vesicular packaging is mediated by the solute carrier
18A-2 (SLC18A2), and its liberation into the synaptic cleft is performed via the SNARE
complex [61,62].
Synaptic 5-HT can activate the 5-HT receptors (especially the postsynaptic receptor
5-HT1A) of the 5-HT-sensitive hippocampal neurons. This is followed by activation medi-
ated by Gi proteins and leads to cell hyperpolarization [33,63-65]. High synaptic 5-HT
concentrations lead to DRN 5-HT1A autoreceptors activation which in turn lead to DRN
neuron hyperpolarization. This hyperpolarization causes a reduction in 5-HT synthesis
that results from a blockade of TPH transcription by BDNF pathway activity and a reduc-
tion in the transport of 5-HT [66-68].
The serotonin transporter (5-HTT), which is expressed by DRN cells, recaptures 5-HT
from the synaptic cleft back into the presynaptic neuron, thereby lowering the synaptic
neurotransmitter concentration when it is excessive. This transporter is one of the main
targets for SSRI antidepressants, which act by blocking 5-HT recapture and lead to higher
5-HT synaptic concentrations [34,35,68]. When the synaptic 5-HT concentration is higher
than normal, the autoreceptor 5-HT1A is desensitized, and this leads to constant synthesis
and transport of 5-HT in DRN cells [36,69].
The synthesis and downregulation of 5-HT in the DRN is also controlled by the brain
derived neurotrophic factor (BDNF). Normally, TRkB is activated when BDNF is ex-
pressed, thereby blocking 5-HT1A autoreceptor synthesis and increasing TPH transcrip-
tion, which leads to an increase in activation of cAMP and PKA. When PKA is active, it
promotes BDNF transcription via phosphorylated CREB [13-15].
Regarding the stress response, stress activates the HPA axis starting with corticotropin
releasing hormone (CRH) and vasopressin (AVP) in the periventricular nucleus (PVN),
which is located in the hypothalamus. Both hormones are transported by the blood stream
to the pituitary gland (PG) where they activate the synthesis of adrenocorticotropic hor-
mone (ACTH). ACTH is then transported by the blood stream to the suprarenal cortex
where it mediates cortisol synthesis [16,41]. When cortisol levels rise in the blood stream,
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corticoid receptors (GRs) and mineralocorticoid receptors (MRs) [41]. Cortisol has a nega-
tive effect on the DRN and the hippocampal 5-HT-sensitive cells. In the DRN, cortisol
blocks TPH transcription by activating GRs and MRs [39]. Cortisol also activates GRs and
MRs in the hippocampus, and this blocks the function of the transcription factor NF-κB,
which in turn leads to weak transcription of the gene encoding the 5-HT1A receptor [70].
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